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The insulin receptor (IR) plays a crucial role in mediating the metabolic and proliferative functions triggered by the peptide
hormoneinsulin.ThereisconsiderableevidencethatabnormalitiesinbothIRexpressionandfunctionmayaccount formalignant
transformation and tumour progression in some human neoplasias, including breast cancer. PPARγ is a ligand-activated, nuclear
hormone receptor implicated in many pleiotropic biological functions related to cell survival and proliferation. In the last decade,
PPARγ agonists—besides their known action and clinical use as insulin sensitizers—have proved to display a wide range of
antineoplastic eﬀects in cells and tissues expressing PPARγ, leading to intensive preclinical research in oncology. PPARγ and
activators aﬀect tumours by diﬀerent mechanisms, involving cell proliferation and diﬀerentiation, apoptosis, antiinﬂammatory,
andantiangiogeniceﬀects.WerecentlyprovidedevidencethatPPARγ andagonistsinhibitIRbynoncanonical,DNA-independent
mechanisms aﬀecting IR gene transcription. We conclude that IR may be considered a new PPARγ “target” gene, supporting a
potential use of PPARγ agonists as antiproliferative agents in selected neoplastic tissues that overexpress the IR.
Copyright © 2009 Daniela P. Foti et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.StructureandBiological
Function of the IR
The peptide hormone insulin regulates the metabolism and
growth of most cells [1]. In target tissues, it is involved
in anabolic processes to produce proteins, polysaccharides,
nucleic acids, and lipids. For this complex task, its action
implicates three major sites of metabolic regulation. At
the plasma membrane, insulin increases the transport of
ions, glucose, and other substrates; in the cytoplasm and
its organelles, it activates a numer of intracellular enzymes,
such as glycogen synthase; in the nucleus, insulin regulates
the synthesis of RNA and DNA. The ﬁrst step in insulin
action is its binding to the IR, a phylogenetically ancient
receptor tyrosine kinase protein embedded in the plasma
membrane of virtually all cells [2–5]. Therefore, the IR plays
a critical role in both directing the hormone to a speciﬁc
target tissue and programming the biological response of
the tissue to the hormone. The IR belongs to the tyrosine
kinase growth factor receptor family. When insulin binds
to the IR, the receptor becomes activated and induces
a cascade of intracellular events that will lead to several
metabolic and growth promoting eﬀects. The IR consists
of two identical extracellular alpha subunits (130kDa) that
house insulin binding domains, and two transmembrane
beta subunits (95kDa) that contain ligand activated tyrosine
kinase activity in their intracellular domains [2–5]. A further
understanding of the nature of the IR and its relationship
to other receptors has been provided by the cloning of
the human IR gene [6–8]. Upon binding of insulin to the
alpha subunits, the receptor is ﬁrst activated by tyrosine
autophosphorylation, and then the IR tyrosine kinase phos-
phorylates various intracellular eﬀector molecules (such as
IRSs) which in turn alters their activity, thereby generating
a biological response [3–5]. In this context, a big eﬀort has
been made by scientists to unravel intracellular signaling2 PPAR Research
pathwaysinvolvingmetabolicormitogenicresponses[9,10].
A bulk of evidences demonstrate that mitogenic stimuli
triggered by growth factors are able to regulate diﬀerent
cell-cycle checkpoints [11]. Insulin stimulation activates
the IR/IRS/PI3K/PDK1 pathway, leading to the activation
of S6K, which is crucial for ribosome biosynthesis, and
necessary for G0-G1 transition. S6k is also stimulated by
TOR, which induces the translation of cell-cycle regulators,
such as cyclin D, mediating progression through the G1
phase. Cyclin D is also a target for the Ras/ERK cascade
induced by insulin, leading to a synergistic eﬀects on cell
proliferation [10–12]( Figure 1).
The interaction between IR and other ligands of the IGF
(insulin-like growth factor) system [13] implicates an even
more complex scenario. The IR exists as two splice variant
isoforms: the IR-B isoform that is responsible for signaling
metabolic responses involved mainly in the regulation of
glucose uptake and metabolism by increasing glucose trans-
porter molecules on the plasma membrane of the insulin-
responsive tissues muscle, liver, and fat, and the IR-A iso-
form,thatisexpressedincertaintumours(suchasmammary
cancers), signals predominantly mitogenic responses and is
capable of binding IGF-II with high aﬃnity [14, 15]. As a
consequence of these cellular activities, abnormalities of IR
expression and/or function can facilitate the development
of several metabolic and neoplastic disorders in humans as
well as in animal models. In addition, hybrid heterodimeric
receptors consisting of insulin and IGF-I receptor subunits
may form and could play a role in receptor signaling in
normal and abnormal tissues [13].
2.MolecularandClinicalSigniﬁcanceof
t h eIRinCanc e r
Dysfunctional IR signaling is implicated in certain common
dysmetabolic disorders, including obesity, type 2 diabetes,
the dysmetabolic syndrome X, and the polycystic ovary
syndrome [16–19]. Also, clinical syndromes due to muta-
tions in the IR gene have been identiﬁed in patients
with genetic forms of severe insulin resistance [20, 21]
A relation between IR and cancer has been established
following the observation that overexpression of functional
IRs can occur in human breast cancer and other epithelial
tumours including ovarian and colon cancer, in which the IR
may exert its oncogenic potential via abnormal stimulation
of multiple cellular signaling cascades, enhancing growth
factor-dependent proliferation and/or by directly aﬀecting
cellmetabolism[22–27].Ontheotherhand,epidemiological
and clinical evidence points to a link between insulin
resistant syndromes such as obesity and type 2 diabetes and
cancer of the colon, liver, pancreas, breast and endometrium.
The mechanistic link between insulin resistance and cancer
is unknown, but constitutive activation of the tyrosine
kinase activity of IR and related downstream signaling
pathways by chronic sustained hyperinsulinemia (a hallmark
of insulin resistance) in these clinical syndromes appears to
have a role in the neoplastic transformation process [28–
30]. Mechanisms due to hyperinsulinemia that promote
malignancy and neoplastic progression include the increase
in IGF-I and sex hormones bioavailability, the increase in
proinﬂammatory cytokines, and oxidative stress. Although
the molecular mechanisms that cause neoplastic transfor-
mation, sustaining tumor progression in the presence of
IR hyperexpression and/or hyperstimulation are not fully
understood, an explanation for increased IR expression in
epithelial tumours has been recently provided by us for
several human breast cancers, in which overexpression of the
transcription factor AP2-α (activator protein 2-α)a c c o u n t e d
forincreasedIRexpressioninneoplasticbreasttissue[31].In
these cases, it has been demonstrated that transactivation of
the IR gene by AP-2α represented a fundamental prerequisite
for AP-2α to activate IR gene transcription in neoplastic
breast tissue. Similarly, a functional link between IR, and
cyclin D1 has been recently described in pancreatic cancer
[32]. Thus, a better understanding of the mechanisms
responsible for increased IR expression may contribute to
identify new therapeutic targets for tumours with abnormal
IR expression and/or function [22, 33].
3. Regulation of the IR Gene Expression
In target cells the IR has been shown to be under the
regulation of hormones, metabolites, and diﬀerentiation
[34]. To further understand the regulation of the IR, we and
others have identiﬁed and analyzed the IR promoter region
[6–8]. This region extends over 1,800 bases 5’ upstream
from the IR gene ATG codon. The IR promoter has no
TATA or CAAT boxes, and includes multiple transcription
initiation sites, reﬂecting a feature common to the pro-
moters of many constitutively expressed genes (so-called
housekeeping genes). The IR is expressed at low levels in
most cells and this expression appears to be driven in part
by a series of GGGCGG repeats (in the region −400 to
−650), which are putative binding sites for the mammalian
transcription factor Sp1. The IR is expressed at higher levels
indiﬀerentiatedtargettissuessuchasmuscleandfat.Atthese
levels, tissue-speciﬁc and ubiquitous nuclear transcription
factors cooperate to induce IR gene transcription. We have
previoulsy identiﬁed two distinct, functionally active DNA
sequences, C2 and E3, within the IR gene promoter, which
had a signiﬁcant ability to drive IR gene transcription [8].
ThemolecularmechanismsregulatingIRgeneexpressionare
being elucidated and evidence has been provided showing
that the architectural transcription factor (High Mobility
G r o u pA 1P r o t e i n )H M G A 1i sr e q u i r e df o rp r o p e rt r a n -
scription of the IR gene in cells expressing IRs. HMGA1
acts on the IR gene promoter as an element necessary for
the formation of a transcriptionally active multiprotein–
DNA complex involving, in addition to the HMGA1 protein,
the ubiquitously expressed transcription factor (speciﬁcity
protein 1) Sp1, and (CCAAT-enhancer binding protein beta)
C/EBPβ. By potentiating the recruitment and binding of Sp1
and C/EBPβ to the IR promoter, HMGA1 greatly enhances
the transcriptional activities of these factors in the context
of the IR gene [35, 36]. Transcriptional activation of the
human IR gene by HMGA1, Sp1, and C/EBPβ requires
the assembly and cooperation among these various nuclearPPAR Research 3
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Figure 1: Upon binding of insulin, the IR undergoes autophosphorylation which enables the receptor to have a kinase activity and
phosphorylates various cytoplasmic substrates, such as IRSs. From this point, signaling proceeds via a variety of signaling pathways (i.e.,
PI3K signaling pathway, Ras and MAP kinase cascade) that are responsible for the metabolic, growth-promoting and mitogenic eﬀects of
insulin.
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Figure 2: Proposed model for the action of PPARγ in the context of the IR gene. AP-2α overexpression accounts for increased IR expression
in both breast cancer cell lines and breast cancer tissues [31]. In this model, interactions between AP-2α and Sp1 in the preinitiation complex
at the IR promoter are facilitated and stabilized by HMGA1. By binding to AP-2α and Sp1, PPARγ may attenuate the stimulatory role of
AP-2α in IR gene expression in breast cancer.
factors at the levels of the two AT-rich sequences of the IR
gene promoter, C2 and E3, which have a signiﬁcant ability
to drive transcription when introduced into mammalian
cells [8, 35, 36]. Qualitative or quantitative defects in these
binding proteins and/or abnormalities in their consensus
sequences within the IR gene may aﬀect IR transcription,
leading to abnormalities in IR gene and protein expression
[21]. Overexpression of IR in cells which normally express
low levels of IR, like epithelial cells, may increase biological
responses to insulin and trigger a ligand-mediated neoplastic
transformation.
4. Pleiotropic Effects of PPARγ
PPARγ is a nuclear hormone receptor [37–39] highly
expressed in adipose tissue, where it regulates adipoge-
nesis and the multiple functions of mature adipocytes
[40–42]. It is also expressed in many other tissues and4 PPAR Research
cell types, including liver, skeletal muscle, breast, prostate,
colon, lung, monocytes, macrophages, and B lineage cells
[43–46]. Besides a fundamental role in lipid metabolism,
PPARγ plays a number of pleiotropic eﬀects, that include a
critical role in placental vascularization, myocardial health,
and embryonic development [47, 48]. It also inﬂuences
the production of cytokines, growth factor release, cell
cycle progression, leading to diﬀerentiation-inducing, anti-
inﬂammatory and anti-proliferative eﬀects [49–51]. PPARγ
generally exterts its biological function as heterodimer
with the retinoid-X-receptor through binding to a speciﬁc
cis-acting sequence on DNA—a peroxisome proliferator
response element (PPRE)—to initiate transcription [37, 50].
T oa c ta st r a n s c r i p t i o nf a c t o r ,P P A R γ requires activation
by binding its ligand. The PPARγ activators identiﬁed so
far include naturally occurring compounds, as some unsat-
urated fatty acids, some anti-inﬂammatory molecules—
such as a prostaglandin J2 metabolite (15-deoxy-D12,14-
PGJ2)—,oxidizedlow-densitylipoprotein(LDL)particles9-
and 13-HODE (hydroxyoctadeca-10E,12Z-dienoic acid) [37,
49], and synthetic compounds, mainly represented by the
thiazolidinediones (TZDs) [52], a class of insulin-sensitizing
drugs widely used in the treatment of type 2 diabetes
mellitus [52, 53]. Most of the known target genes that are
transcriptionally activated by PPARγ belong to the pathway
of metabolism and transport of lipids [42, 49]. However,
PPARγ m a ya l s or e p r e s sg e n et r a n s c r i p t i o n .I nm o n o c y t e s
and macrophages, for example, it reduces IL-4 (interleukin-
4) expression. Also, it reduces proinﬂammatory proteins,
like (tumor necrosis factor α)T N F - α, (interleukin-1) IL-1,
(inducible nitric oxide synthetase) iNOS, and proinﬂamma-
tory transcription factors such as (activator protein-1) AP-
1, (signal transducer and activator of transcription) STAT,
and (nuclear factor-kB) NF-kB [54–56]. The mechanisms
by which this occurs is unclear. It is generally accepted that
in the unliganded state, PPARγ can form weak interactions
with (nuclear receptor corepressor) NcOR and (silencing
mediator of retinoid and thyroid hormone receptors) SMRT
t or e p r e s st a r g e tg e n ee x p r e s s i o n[ 57]. Target genes that
mediate the anticancer activity of the activated PPARγ are
still largely undeﬁned and can be related to a wide range
of processes including tumour cell diﬀerentiation, apoptosis,
anti-proliferative eﬀects, and modulation of angiogenic
phenotype of the tumour microenvironment.
5. Effects of PPARγ o nt h eI RGe n e
Studies aimed at understanding whether IR could con-
stitute a target gene for PPARγ have been performed in
several cultured cell lines expressing variable amounts of
PPARγ. In HepG2 human hepatoma cells IRs are relatively
abundant, while endogenous PPARγ is barely detectable.
Protein expression studies showed that IR protein content
was considerably reduced in HepG2 cells overexpressing
PPARγ (∼50%lessthancontrolcells),andthisreductionwas
more pronounced in PPARγ-overexpressing cells exposed
to TZDs. It has been postulated that PPARγ could aﬀect
IR content by blunting IR gene transcription. To this end,
reporter gene studies have been performed using the pIR-
CAT recombinant vector that contains the entire 5’-ﬂanking
region of the human IR gene [36]. Forced expression of
PPARγ in HepG2 cells transfected with pIR-CAT determined
a ∼50% reduction in CAT activity that was similar to
the reduction observed in cells exposed to rosiglitazone
alone, and resulted more marked in PPARγ-overexpressing
cells simultaneously treated with TZD rosiglitazone. These
ﬁndings were conﬁrmed in PPARγ overexpressing MCF-7
human breast cancer cells, a cell line naturally expressing
only detectable levels of PPARγ [58], and 3T3-L1 adipocytes
producing relatively high amounts of endogenous PPARγ
[59].Exposureofbothcelllinestoeitherrosiglitazoneand/or
ciglitazone considerably reduced IR gene transcription [60].
When the recombinant plasmid pCAT-C2 was transfected
into HepG2 cells (and the other cell lines), PPARγ,a n d
TZDs, either alone or in combination, inhibited pCAT-C2
activity to the same extent than they did in HepG2 cells
transfected with the full-length pCAT-IR promoter, indicat-
ing that interference of PPARγ and agonists with IR gene-
transcription machinery occurs at the level of the proximal
promoter region, C2. This conclusion was supported by
the observation that in experiments using the pCAT-E3
reporter vector, containing the more distant E3 sequence of
the IR gene, no eﬀects on CAT activity were observed in
cells exposed to PPARγ and/or TZDs. However, no PPRE
have been identiﬁed on the promoter region of the IR gene.
A similar observation has been previously provided by us
for the transcription factor AP-2α, for which DNA-binding
activity was undetectable within the IR gene promoter, and
transactivation of the IR gene by AP-2α occurred indirectly
through physical and functional cooperation with HMGA1
and Sp1 [31]. Therefore, we postulated that PPARγ could
perturb IR gene transcription via noncanonical mechanisms
interfering with the “enhanceosome” complex formation
implicated in transcriptional activation of the IR gene. This
hypothesis was conﬁrmed by GST-pull-down studies, fol-
lowed by electrophoresis mobility shift assay and chromatin
immunoprecipitation analyses, demonstrating that PPARγ
physically interacted with Sp1, AP-2α (in selected cell lines)
and, to a lesser extent, with C/EBPβ and prevented binding
ofAP-2αtoSp1protein,aswellasofSp1andC/EBPβtotheir
DNA consensus sites within the IR gene locus [60].
Thus, overexpression and/or activation of PPARγ may
adversely aﬀect IR gene transcription in the absence of PPRE
on the IR gene promoter. By causing a displacement of Sp1,
AP-2α,a n dC /EBPβ,P P A R γ may play signiﬁcant molecular
roles in the transcriptional activities of these factors in the
context of the IR gene, both in physiology and pathology
(Figure 2). These ﬁndings are consistent with the notion
that IR is regulated by PPARγ through PPRE-independent
mechanisms. Further, they are in line with the hypothesized
antineoplastic eﬀects of PPARγ and TZD, and support a
potential use of PPARγ-agonists as antiproliferative agents in
selected neoplastic tissues, overexpressing IRs.
6. Discussion
The IR is critical in the insulin-mediated eﬀects on cell
metabolismandcellgrowth.VariousstudieshaveshownthatPPAR Research 5
IRs are increased in most human breast cancers, and both
ligand-dependent malignant transformation and increased
cell growth occur in cultured breast cells overexpressing the
IR [31, 61, 62]. Also, overexpression of functional IRs has
been involved in thyroid carcinogenesis [63]. In all these
cases, the IR can exert its oncogenic potential in malignant
cells via abnormal stimulation of multiple cellular signaling
cascades, enhancing growth factor-dependent proliferation
and/or by directly aﬀecting cell metabolism.
The TZDs are insulin-sensitizing drugs that improve
insulin sensitivity in insulin-resistant states such as type 2
diabetes mellitus and obesity. These drugs are high-aﬃnity
ligands for the nuclear receptor PPARγ, which regulate
transcription of target genes involved in the homeostasis of
nutrients. In addition to the eﬀects on lipid and glucose
metabolism, many evidences have shown that PPARγ and
its ligands play an important role in modulating many
processes, including cell proliferation and diﬀerentiation.
Both breast and thyroid neoplastic cells express PPARγ,a n d
PPARγ agonists have been shown to inhibit proliferation in
these and other cell systems [58, 64]. In this light, studies
have been performed to assess the eﬀects of PPARγ on
IR expression. Results from our group have shown that
IR gene transcription and expression were reduced in cells
with forced PPARγ expression, or TZD-induced PPARγ
activation. Cotreatment with both PPARγ and TZDs further
reduced IR protein and mRNA. In this context, treatment
with speciﬁc PPARγ s i R N Ao rw i t hP P A R γ antagonists
should be necessary to better understand PPARγ-dependent
eﬀects of TZDs. If from one hand this seems to exclude the
possibility that TZDs may act as insulin sensitizers through
the IR, on the other hand this results are compatible with the
pleiotropic eﬀects of PPARγ. In this regard, the IR may be
considered a new “target” gene that accounts for the antim-
itogenic response to PPARγ and its agonists, and this is the
ﬁrst description of a cell membrane tyrosine kinase receptor
involved in PPARγ induced antiproliferative mechanisms.
We showed that PPARγ physically interacted with Sp1,
C/EBPβ, and AP-2α reducing IR gene transcription in the
absence of PPARγ DNA-binding sites on the IR gene. We
suggested that, in the absence of PPRE in the context of the
IR promoter, this nuclear receptor may produce its adverse
eﬀects on IR gene expression by interacting physically
with these factors, thus reducing their availability to the
basic transcription machinery of the IR gene. With a sim-
ilar mechanism involving Sp1/PPARγ protein interaction,
PPARγ has been shown to exert an antiproliferative role by
suppressing transcription of the thromboxane receptor, the
cyclin-dependent kinase inhibitor p21, and the ﬁbronectin
genes [65–67]. The molecular mechanism by which PPARγ
inhibits IR gene expression is therefore in agreement with
the increasing repertoire of “noncanonical” PPARγ target
genes that now encompasses non-PPRE containing genes
[50]. Many potential “target” genes of PPARγ, regulated by
DNA-independent mechanisms, have been already reported,
including bcl-2 (oncogene B-cell leukemia 2, β-catenin,
and the PTEN (phosphatase and tensin homolog) tumor
suppressor gene [68–70]. However, how PPARγ and its
agonists may induce their antiproliferative eﬀects is not fully
understood yet. Recently, non-genomic cross-talks between
PPARγ and cytoplasmic proteins, like (extracellular signal
regulated kinase) ERK 1/2, and (mitogen-activated protein
kinase) MAPK kinases, have been reported in cancer cells
and functional importance has been given to the subcellular
localization of PPARγ [71, 72]. In this regard, in PC-3
prostate cancer cells, IGF-1R signaling has been shown to
be attenuated by rosiglitazone via non-genomic action on
ERK 1/2, and protein kinase AKT phosphorylation [73].
Therefore, both nuclear and cytoplasmic events may be
theoretically operative in inhibiting the mitogenic signals
common to the receptors of the IGF system (IR, IGF-1R and
hybrid IR/IGF-1R).
The last three decades of medical research examining the
molecular pathogenesis of cancers have provided compelling
evidence for the universal disruption of the cell cycle in
human tumours, and recent studies have demonstrated a
critical interface between hormonal signaling and the cell
cycle [74]. In this context, mitogens like insulin, via the
IR, may promote the progression through the G1 phase
by inducing competence of the cyclin D1/cyclin-dependent
kinase 4 (CDK4) complex. It has been previously reported
that the PPARγ agonists inhibit cyclin D1 [75]. Our ﬁndings
on IR and PPARγ support the conclusion that PPARγ and
TZDs may interfere with the hormonal control of the cell
cycle, at least in part, through the inhibition of the IR. Over
the last decade, PPARγ has emerged as an important drug
target in type 2 diabetes mellitus [76], and TZDs are widely
used for treatment of diabetic patients. However, conﬂicting
results on the procarcinogenic and antitumorigenic eﬀects of
TZDsinhumanswithdiabetescanbefoundintheliterature.
For instance, whereas a population based report showed that
TZDs were associated with reduced risk of lung cancer in
patients with diabetes [77], a possible association between
cancer and the use of TZD has been reported later in type 2
diabetic patients [78]. Thus it is tempting to suppose that IR
gene may be considered a new anticancer target for PPARγ,
providing further evidence for the use of TZDs as anti-
proliferative agents in selected tumours overexpressing the
IR.
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